Cargando…
Updates in Anthracycline-Mediated Cardiotoxicity
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of cancer therapies and the short- and long-term quality of life. Anthracyclines are currently used to treat many cancers, including the various forms of leukemia, lymphoma, melanoma, uterine, breast, and ga...
Autores principales: | Nebigil, Canan G., Désaubry, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240592/ https://www.ncbi.nlm.nih.gov/pubmed/30483123 http://dx.doi.org/10.3389/fphar.2018.01262 |
Ejemplares similares
-
Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
por: Audebrand, Anais, et al.
Publicado: (2020) -
Discovery of GPCR ligands for probing signal transduction pathways
por: Brogi, Simone, et al.
Publicado: (2014) -
The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014) -
Flavaglines Alleviate Doxorubicin Cardiotoxicity: Implication of Hsp27
por: Bernard, Yohann, et al.
Publicado: (2011) -
Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies
por: Hsu, Po-Yen, et al.
Publicado: (2021)